Detecting Nucleic Acid By Specific Antibody, Protein Or Ligand-receptor Binding Assay Patents (Class 435/6.19)
-
Publication number: 20140255948Abstract: The present invention relates a simple method for evaluating free eukaryotic cell nuclei for biomarkers of DNA damage and/or transcription factor activation, activity, or expression levels and/or epigenetic modifications to chromatin or chromatin-associated factors. The invention also teaches useful strategies for combining nuclear biomarkers into a matrix of endpoints that are capable of elucidating genotoxicants' primary mode of DNA-damaging activity. Kits for conducting methods according to the invention are also described.Type: ApplicationFiled: March 7, 2014Publication date: September 11, 2014Applicant: Litron Laboratories, Ltd.Inventors: Stephen D. Dertinger, Steven M. Bryce, Jeffrey C. Bemis
-
Patent number: 8822168Abstract: The present invention includes assays and kits for detecting the assembly of an RNA binding protein-RNA complex and for detecting the activity of an RNA binding protein.Type: GrantFiled: March 10, 2006Date of Patent: September 2, 2014Assignee: The Trustees of the University of PennsylvaniaInventors: Gideon Dreyfuss, Lili Wan, Elizabeth Ottinger
-
Patent number: 8822160Abstract: The invention relates to transmembrane protein pore for use in detecting a analyte in a sample. The pore comprises a molecular adaptor that facilitates an interaction between the pore and the analyte. The adaptor is covalently attached to the pore in an orientation that allows the analyte to be detected using the pore.Type: GrantFiled: October 6, 2008Date of Patent: September 2, 2014Assignee: Isis Innovation LimitedInventors: John Hagan Bayley, Haichen Wu, Giovanni Maglia, Yann Astier
-
Patent number: 8815517Abstract: The identification and evaluation of mRNA and protein targets associated with mRNP complexes and implicated in the expression of proteins involved in common physiological pathways is described. Effective targets are useful for treating a disease, condition or disorder associated with the physiological pathway.Type: GrantFiled: December 4, 2002Date of Patent: August 26, 2014Assignee: Ribonomics, Inc.Inventors: Jack D. Keene, Scott A. Tenenbaum, Craig C. Carson, William C. Phelps
-
Publication number: 20140234853Abstract: Provided herein are compositions and systems for use in polymerase-dependent, nucleotide transient-binding methods. The methods are useful for deducing the sequence of a template nucleic acid molecule and single nucleotide polymorphism (SNP) analyses. The methods rely on the fact that the polymerase transient-binding time for a complementary nucleotide is longer compared to that of a non-complementary nucleotide. The labeled nucleotides transiently-binds the polymerase in a template-dependent manner, but does not incorporate. The methods are conducted under any reaction condition that permits transient binding of a complementary or non-complementary nucleotide to a polymerase, and inhibits nucleotide incorporation.Type: ApplicationFiled: December 16, 2013Publication date: August 21, 2014Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Peter VANDER HORN, Cheng-Yao CHEN, Guobin LUO, Michael PREVITE, Jamshid TEMIROV, Theo NIKIFOROV, Zhaohui ZHOU, Hongye SUN, Yufang WANG, Stefanie Yukiko NISHIMURA, Hongyi WANG, Marian PERIS, Barnett ROSENBLUM, Michael PHELAN
-
Publication number: 20140220160Abstract: Methods and products for detecting in vitro the presence of damage on DNA or the presence of a biological response to damage on DNA at the molecular level. Molecular Combing or other nucleic acid stretching methods are employed together with compounds reacting with DNA, probes binding DNA, or nucleic acid monomers, especially labeled nucleic acid monomers.Type: ApplicationFiled: April 11, 2014Publication date: August 7, 2014Applicant: GENOMIC VISIONInventors: Lucia CINQUE, Aaron Bensimon
-
Publication number: 20140220587Abstract: The disclosure provides methods to assemble genomes of eukaryotic or prokaryotic organisms. The disclosure further provides methods for haplotype phasing and meta-genomics assemblies.Type: ApplicationFiled: January 31, 2014Publication date: August 7, 2014Applicant: The Regents of the University of CaliforniaInventors: Richard E. Green, JR., Liana F. Lareau
-
Publication number: 20140213460Abstract: Methods relating to obtaining libraries of YY1-binding long non-coding RNAs, libraries obtained thereby, and methods of use thereof.Type: ApplicationFiled: July 3, 2012Publication date: July 31, 2014Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Jeannie T. Lee, Yesu Jeon
-
Publication number: 20140206013Abstract: An imaging method utilizing a split peroxidase is described herein. Imaging methods involve contacting a cell with a split peroxidase and a substrate thereof to allow conversion of a substrate into a product via an enzymatic reaction catalyzed by the reconstitute split peroxidase. Also disclosed herein are split peroxidases, related products and kits.Type: ApplicationFiled: January 16, 2014Publication date: July 24, 2014Applicant: Massachusetts Institute of TechnologyInventors: Alice Y. Ting, Jeffrey Daniel Martell
-
Publication number: 20140206015Abstract: The invention relates to a method for detecting and measuring the presence of mono-nucleosomes and oligo-nucleosomes and the use of such measurements for the detection and diagnosis of disease.Type: ApplicationFiled: August 31, 2012Publication date: July 24, 2014Applicant: Singapore Volition Pte LimitedInventor: Jacob Vincent Micallef
-
Publication number: 20140206014Abstract: The invention relates to a method for detecting and measuring the presence of mono-nucleosomes and oligo-nucleosomes and nucleosomes that contain particular histone variants and the use of such measurements for the detection and diagnosis of disease. The invention also relates to a method of identifying histone variant biomarkers for the detection and diagnosis of disease and to biomarkers identified by said method.Type: ApplicationFiled: August 31, 2012Publication date: July 24, 2014Inventor: Jacob Vincent Micallef
-
Publication number: 20140186850Abstract: The invention provides methods for delivery of payloads to targets in samples using non-sterically hindered complexes. The invention further provides reagents and kits for practicing the methods of the invention. The invention also provides methods for preparation of reagents for use in the methods of the invention.Type: ApplicationFiled: December 19, 2013Publication date: July 3, 2014Applicant: AKRIVIS TECHNOLOGIES, LLCInventors: Joel Berniac, Peter Donovan, Ban-An Khaw, Vishwesh Patil
-
Publication number: 20140162280Abstract: The invention relates to a method for automated determination of immunofluorescent foci by means of an immunofluorescence assay using synthetic calibration particles, in addition to a system and kit for carrying out the method. In a preferred embodiment the method is characterized in that the immunofluorescent foci are gamma H2Ax foci.Type: ApplicationFiled: June 4, 2012Publication date: June 12, 2014Applicants: MEDIPAN GMBHInventor: Dirk Roggenbuck
-
Patent number: 8715924Abstract: A process is disclosed for determining the concentration of nucleic acids in a sample in a microfluidic device. In at least one embodiment, the method includes a) introducing the sample into a first chamber, b) carrying out a number of cycles of an amplification reaction to be carried out in cycles for amplifying nucleic acids, c) transferring a defined volume which is a fraction of the volume of the first chamber and which has amplified nucleic acids into a second chamber and replacing the transferred defined volume with fresh reagents for the amplification reaction, d) determining the concentration of the amplified nucleic acids in a second chamber equipped with an element to determine concentrations, and e) repeating steps b)-d) until a concentration of the amplified nucleic acids which is within a range is determined in the second chamber. An arrangement is further disclosed.Type: GrantFiled: June 13, 2007Date of Patent: May 6, 2014Assignee: Siemens AktiengesellschaftInventors: Walter Gumbrecht, Jörn Mosner, Sebastian Schmidt
-
Patent number: 8703417Abstract: The invention is directed to enhanced methods for detecting an analyte of interest in situ, by immunoassay, or by hybridization comprising binding an enzyme-labeled conjugate molecule to an analyte of interest in the presence of a redox-inactive reductive species and a soluble metal ion. The enzyme catalyzes the conversion of the inactive reductive species to an active reducing agent, which in turn reduces the metal ion to a metal atom thereby providing an enhanced means of detecting the analyte via metal deposition.Type: GrantFiled: June 21, 2012Date of Patent: April 22, 2014Assignee: Ventana Medical Systems, Inc.Inventors: Christopher Bieniarz, Michael Farrell
-
Patent number: 8702948Abstract: Disclosed are a method and apparatus that use an electric field for improved biological assays. The electric field is applied across a device having wells, which receive reactants, which carry a charge. The device thus uses a controllable voltage source between the first and second electrodes, which is controllable to provide a positive charge and a negative charge to a given electrode. By controlled use of the electric field charged species in a fluid in a fluid channel are directed into or out of the well by an electric field between the electrodes. The present method involves the transport of fluids, as in a microfluidic device, and the electric field-induced movement of reactive species according to various assay procedures, such as DNA sequencing, synthesis or the like.Type: GrantFiled: September 14, 2012Date of Patent: April 22, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Mostafa Ronaghi, Tarun Khurana, Juan G. Santiago
-
Patent number: 8691589Abstract: The method of the present disclosure determines whether a target DNA forms a G-quadruplex using a phenomenon in which thioflavin T generates a strong fluorescence when reacted with the G-quadruplex in the presence of potassium ions.Type: GrantFiled: May 22, 2013Date of Patent: April 8, 2014Assignee: Panasonic CorporationInventor: Daisuke Miyoshi
-
Patent number: 8685781Abstract: A method of forming an optoelectronic device. The method includes providing a deposition surface and contacting the deposition surface with a ligand exchange chemical and contacting the deposition surface with a quantum dot (QD) colloid. This initial process is repeated over one or more cycles to form an initial QD film on the deposition surface. The method further includes subsequently contacting the QD film with a secondary treatment chemical and optionally contacting the surface with additional QDs to form an enhanced QD layer exhibiting multiple exciton generation (MEG) upon absorption of high energy photons by the QD active layer. Devices having an enhanced QD active layer as described above are also disclosed.Type: GrantFiled: July 20, 2011Date of Patent: April 1, 2014Assignee: Alliance for Sustainable Energy, LLCInventors: Octavi Escala Semonin, Joseph M. Luther, Matthew C. Beard, Hsiang-Yu Chen
-
Publication number: 20140087390Abstract: A protocol and system for determining sites at which proteins directly bind to DNA or RNA, modify other proteins including histones, or bind to other proteins as well as determining sites at which DNA or RNA is modified is described herein. A simplified, highly accurate method for studying protein interactions with DNA or RNA and sites of DNA or RNA modification using nanodetector systems is provided.Type: ApplicationFiled: September 25, 2013Publication date: March 27, 2014Applicant: NABsys, Inc.Inventors: John S. Oliver, John Thompson
-
Patent number: 8673567Abstract: A method and kit for detecting the presence of a target sequence in a polynucleotide analyte contained in a sample are disclosed. In practicing the method, the sample is mixed with a single-stranded DNA target probe having a sequence capable of hybridizing with the target sequence, under conditions effective to form a double-stranded complex of the analyte and the single-stranded DNA target probe, and the single-stranded DNA target probe in the complex is reacted in the presence of a polymerase and one to three nucleotide triphosphates, to add a selected one or more target-directed nucleotide bases to single-stranded DNA target probe's 3? end to produce a modified probe. The modified probe is hybridized with a single-stranded DNA detection probe, the two probes are ligated to form a two-probe ligation product, and the presence of the ligation product is detected.Type: GrantFiled: March 8, 2007Date of Patent: March 18, 2014Assignee: Atila Biosystems, Inc.Inventors: Youxiang Wang, Wenjing Tao
-
Publication number: 20140065634Abstract: Provided herein are antibodies for determining the concentration of anti-dsDNA and anti-chromatin antibodies in biological samples.Type: ApplicationFiled: September 5, 2013Publication date: March 6, 2014Applicant: Bio-Rad Laboratories, Inc.Inventors: Roger Walker, John Wesley Breneman, III
-
Patent number: 8642257Abstract: Described are diagnostic and pharmaceutical compositions comprising a microorganism or cell containing a DNA sequence encoding a detectable protein or a protein capable of inducing a detectable signal, e.g. a luminescent or fluorescent protein, and, in a particular embodiment, furthermore (a) DNA sequence(s) encoding (a) protein(s) suitable for tumor therapy and/or elimination of metastatic tumors, e.g. a cytotoxic or cytostatic protein.Type: GrantFiled: July 31, 2002Date of Patent: February 4, 2014Assignee: Genelux CorporationInventors: Aladar A. Szalay, Yong A. Yu, Shahrokh Shabahang, Tatyana Timiryasova
-
Patent number: 8637255Abstract: The nucleic acid sequences of adeno-associated virus (AAV) serotype 1 are provided, as are vectors and host cells containing these sequences and functional fragments thereof. Also provided are methods of delivering genes via AAV-1 derived vectors.Type: GrantFiled: March 16, 2011Date of Patent: January 28, 2014Assignee: The Trustees of the University of PennsylvaniaInventors: James M. Wilson, Weidong Xiao
-
Patent number: 8637257Abstract: The present invention relates to methods for identifying agents capable of inhibiting the expression or activity of proteins involved in the processes modulating osteoclastogenesis, which inhibition is useful in the prevention and/or treatment of bone and joint degenerative diseases and diseases involving aberrant activity or differentiation of osteoclasts. In particular, the present invention provides methods for identifying agents for use in the prevention and/or treatment of rheumatoid arthritis.Type: GrantFiled: June 19, 2008Date of Patent: January 28, 2014Assignee: Galapagos NVInventors: Reginald Christophe Xavier Brys, Nick Ernest René Vandeghinste
-
Publication number: 20140024016Abstract: The present invention relates to novel lateral flow devices using two dimensional features, preferably, uniform two dimensional test and control features, to provide flow control information, to function as an internal control and/or to provide internal calibration information for the test device. The present invention also relates to methods for using the lateral flow devices to provide flow control information, to function as an internal control and/or to provide internal calibration information for the test device.Type: ApplicationFiled: March 13, 2013Publication date: January 23, 2014Inventors: Brendan O'FARRELL, Thomas C. TISONE
-
Patent number: 8632972Abstract: The present invention includes compositions, methods and kits for the identification of a polypeptide that binds to a predetermined RNA sequence. The invention comprises, in part, a photoreactive moiety to aid in identification of such a polypeptide.Type: GrantFiled: June 20, 2006Date of Patent: January 21, 2014Assignee: The Trustees of the University of PennsylvaniaInventors: James Eberwine, Ulo Langel, Kalle Kilk, Jennifer Zielinski
-
Publication number: 20130337465Abstract: The present invention relates a method for the enumeration of mammalian cell micronuclei, while distinguishing micronuclei from the chromatin of dead and dying cells. The method utilizes differential staining of chromatin from dead and dying cells, to distinguish the chromatin from micronuclei and nuclei that can be detected based upon fluorescent emission and light scatter following exposure to an excitatory light source. Counting of micronuclei events relative to the number of nuclei can be used to assess the DNA-damaging potential of a chemical agent, the DNA-damaging potential of a physical agent, the effects of an agent which can modify endogenously-induced DNA damage, and the effects of an agent which can modify exogenously-induced DNA damage. Kits for practicing the invention are also disclosed.Type: ApplicationFiled: August 16, 2013Publication date: December 19, 2013Applicant: Litron Laboratories, Ltd.Inventors: Stephen D. DERTINGER, Sian E. CAIRNS, Svetlana L. AVLASEVICH, Dorothea K. TOROUS
-
Publication number: 20130337464Abstract: The invention relates to a process involving analyzing the presence of arsenic in a sample, comprising the following steps: (a) contacting a sample suspected of containing arsenic on a solid support functionalized with a DNA fragment comprising an ArsR protein binding site, site on which an ArsR protein is attached, the presence arsenic causing separation of the ArsR protein from the DNA fragment; (b) incubation of the sample in contact with the said support; (c) elimination of ArsR protein separated from the DNA fragment by washing the support after the incubation carried out in step (b); and (d) analyzing by an ELISA technique to detect the presence or absence of ArsR protein remaining attached to the DNA fragment.Type: ApplicationFiled: February 23, 2012Publication date: December 19, 2013Applicant: UNIVERSITE DE LORRAINEInventor: Pascal Poupin
-
Publication number: 20130337445Abstract: A method and apparatus for the discovery, development and clinical application of multiplex synthetic assays based on patterns of free radicals, indicators of oxidative or nitrosative stress, or indicators of the redox state of biologic fluids and tissue specimens. These individual measurements are combined into an optimized clinical biomarker using known well-known mathematical, machine learning techniques.Type: ApplicationFiled: June 19, 2013Publication date: December 19, 2013Inventor: Norman A. Paradis
-
Patent number: 8603996Abstract: An extensible RNA-based framework for engineering ligand-controlled gene regulatory systems, called ribozyme switches, that exhibit tunable regulation, design modularity, and target specificity is provided. These switch platforms typically contain a sensor domain, comprised of an aptamer sequence, and an actuator domain, comprised of a hammerhead ribozyme sequence. A variety of modes of standardized information transmission between these domains can be employed, and this application demonstrates a mechanism that allows for the reliable and modular assembly of functioning synthetic hammerhead ribozyme switches and regulation of ribozyme activity in response to various effectors. In some embodiments aptamer-regulated cis-acting hammerhead ribozymes are provided.Type: GrantFiled: March 13, 2012Date of Patent: December 10, 2013Assignee: California Institute of TechnologyInventors: Katie Galloway, Christina D. Smolke, Maung Nyan Win
-
Publication number: 20130323747Abstract: The present invention relates to a method of detecting the presence, amount or subcellular location of an antigenic structure of interest in a cell.Type: ApplicationFiled: May 20, 2013Publication date: December 5, 2013Applicant: Ludwig-Maximilians-Universitat MunchenInventors: Ulrich Rothbauer, Heinrich Leonhardt
-
Publication number: 20130323746Abstract: The invention provides a method for detection of inflammatory disease in a subject that comprises assaying a test sample of peripheral blood from the subject for a marker of DNA damage. An elevated amount of marker present in the test sample compared to control sample is indicative of inflammatory disease activity, including sub-clinical inflammation. The method can be adapted for quantitatively monitoring the efficacy of treatment of inflammatory disease in a subject. Markers of DNA damage include single- and/or double-stranded breaks in leukocytes, oxidative DNA damage in leukocytes, or a marker of nitric oxide oxidative activity (protein nitrosylation in leukocytes). The inflammatory disease can be inflammatory bowel disease (ulcerative colitis or Crohn's disease).Type: ApplicationFiled: April 18, 2013Publication date: December 5, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: AYA M. WESTBROOK, ROBERT H. SCHIESTL, BO WEI, JONATHAN BRAUN
-
Publication number: 20130316394Abstract: The invention relates to a method of detecting viable cells in a cell sample, using a membrane permeable fluorescent label that permeates both viable and non-viable cells and a membrane impermeant quencher that selectively permeates non-viable cells.Type: ApplicationFiled: May 2, 2013Publication date: November 28, 2013Applicant: Charles River Laboratories, Inc.Inventor: Charles River Laboratories, Inc.
-
Patent number: 8586349Abstract: The present invention concerns a method for the detection of an analyte in a droplet of fluid comprising the steps of providing a solid phase with a hydrophobic surface comprising at least one capture zone on which at least one binding agent with affinity for the analyte is immobilized, applying said droplet to the surface of said solid phase, applying a force that makes the droplet travel along the surface of said solid phase along a predetermined path thereby allowing the droplet to repeatedly contact said binding agent on the capture zone, applying conditions wherein said analyte is allowed to bind to said binding agent and detecting a complex of analyte and binding reagent at the position of the capture zone. The effect of a moving droplet is that the reactants in the droplet are well mixed which eliminates the risk of diffusion limitation. Such advantageous mixing is not obtained with conventional assays in which the surface is continuously exposed to the liquid.Type: GrantFiled: August 6, 2001Date of Patent: November 19, 2013Assignee: Biomerieux B.V.Inventors: Thomas Augustinus Maria Beumer, Petrus Franciscus Hendrikus M. Verheijden, Hendrik Sibolt van Damme
-
Patent number: 8580502Abstract: Four and a Half LIM domains protein 1 (FHL-1) mutations at positions 128 or 224 that are associated with X-linked muscular myopathy, methods of screening subjects to identify those susceptible to muscular myopathy including muscular dystrophy and cardiomyopathy and kits.Type: GrantFiled: June 4, 2008Date of Patent: November 12, 2013Assignee: Centre for Addiction and Mental HealthInventors: John B. Vincent, Christian Windpassinger, Stefan Quasthoff
-
Patent number: 8580515Abstract: A method for surface modification of single walled carbon nanotubes is described. In one embodiment, the method includes the steps of providing a detergent solution, adding a plurality of single walled carbon nanotubes into the detergent solution, performing a first sonication to disperse the single walled carbon nanotubes in the detergent solution, and performing a second sonication after the first sonication to make detergent encased single walled carbon nanotubes. At least one of the plurality of single walled carbon nanotubes is at least partially wrapped by one or more detergent molecules to make it a detergent encased single walled carbon nanotube. In one embodiment, the detergent comprises SDS, PSS or a combination of them. The surface modified carbon nanotubes can be used to detect a chemical compound by associating a solution of the surface modified nanotubes with the chemical compound and optically detecting a chemical property change of the solution.Type: GrantFiled: November 17, 2006Date of Patent: November 12, 2013Assignee: Board of Trustees of the University of ArkansasInventors: Wei Zhao, Chulho Song
-
Patent number: 8580516Abstract: The present invention is a method for detecting the extent of DNA damage in a subject suspected of having DNA damage wherein the damage results in the formation of aldehyde moieties in DNA comprising, obtaining a DNA sample from the subject, combining the DNA sample with a fluorescent, chromogenic, pro-fluorescent or pro-chromogenic hydrazine compound to from a fluorescent DNA, detecting the presence of the fluorescent DNA by monitoring the fluorescent emission and quantitating the fluorescent emission thereby determining the extent of DNA damage in the subject.Type: GrantFiled: September 8, 2009Date of Patent: November 12, 2013Assignee: University of ChicagoInventors: David A. Schwartz, Stephen J. Kron
-
Patent number: 8581035Abstract: The invention provides methods for identifying regenerated transformed plants and differentiated transformed plant parts, obtained without subjecting plant cells to selective conditions prior to regenerating the cells to obtain differentiated tissues. In particular embodiments, the plant cells are corn plant cells. Methods for growing and handling plants, including identifying plants that demonstrate specific traits of interest are also provided.Type: GrantFiled: August 31, 2007Date of Patent: November 12, 2013Assignee: Monsanto Technology LLCInventor: Jyoti R. Rout
-
Publication number: 20130295021Abstract: Provided are human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: October 11, 2011Publication date: November 7, 2013Inventors: Feng Chen, Jan Grimm, Jean-Luc Baeriswyl, Roger Nitsch, Christoph Hock
-
Publication number: 20130288264Abstract: A sample extraction method with improved sensitivity for capture of trace amounts of target by utilizing a target-specific enzyme, and covalently bonding the target for capture and immobilization on an activated surface.Type: ApplicationFiled: December 17, 2012Publication date: October 31, 2013Inventor: Youn-Hi Woo
-
Patent number: 8563327Abstract: The present invention provides, as a novel diagnosis marker for type 1 diabetes mellitus, a type 1 diabetes mellitus diagnostic composition comprising alanyl-tRNA synthetase, glycyl-tRNA synthetase, asparaginyl-tRNA synthetase, or tryptophanyl-tRNA synthetase, a diagnostic kit comprising the same, and a diagnostic method using the same. The composition, the kit, and the method, according to the present invention, may be used for early diagnosis and confirmed diagnosis of type 1 diabetes mellitus because type 1 diabetes mellitus can be easily diagnosed from a patient sample.Type: GrantFiled: August 5, 2011Date of Patent: October 22, 2013Assignees: Seoul National University Hospital, SNU R&DB FoundationInventors: Sang Gyu Park, Kyong Soo Park, Sunghoon Kim
-
Publication number: 20130273556Abstract: Disclosed are methods for suppressing or altering gene expression by locked nucleic acids that have high binding affinity for target sequences in genomic DNA. The present methods include a step of recombination to insert a foreign DNA fragment into a specific target site in a genome with greater efficiency than with current techniques. Using a protein to anchor a locked nucleic acid targeting construct at a specific site, DNA recombination between that site and foreign DNA is induced by employing the cell's innate repair machinery. As a result of this recombination, gene transcription can be effectively suppressed. The present methods work in all mammalian cells, and provide a rapid methodology to examine gene function. The foreign DNA can carry markers for ease of screening. The technique is applied in the production of stable cell lines with inserted or deleted genes.Type: ApplicationFiled: November 4, 2011Publication date: October 17, 2013Applicant: US GOVERNMENT, DEPARTMENT OF VETERANS AFFAIRSInventors: Andrew R. Hoffman, Jianqun Ling
-
Publication number: 20130273063Abstract: Methods of tests that assess the expression of DPC4 (SMAD4) to identify subjects with pancreatic cancer that are likely or unlikely to respond to treatment with BTK inhibitors; methods of treating subjects based on identification of said subjects as likely to respond to treatment with BTK inhibitors; therapeutic targets for cancers, particularly cancers with inactivated DPC4 gene or protein; methods of screening of new therapeutic agents using the target; pharmaceutical composition comprising BTK inhibitors, such as PCI-32765 or derivatives thereof, for cancer treatment; and kits that facilitate the performance of the methods are disclosed.Type: ApplicationFiled: April 19, 2011Publication date: October 17, 2013Applicant: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTEInventors: Haiyong Han, Daniel Von Hoff, Caroline Huynh Diep, Hongwei Yin
-
ANTIBODY-LINKED IMMUNO-SEDIMENTATION AGENT AND METHOD OF ISOLATING A TARGET FROM A SAMPLE USING SAME
Publication number: 20130266930Abstract: The present disclosure is directed to antibody-linked immuno-sedimentation agent, the antibody being linked to a sedimentation agent by a non-antigen binding region of the antibody, and a method of isolating a target from a sample using the antibody-linked immuno-sedimentation agent. The methods involve forming a mixture including a sample with an antibody linked immuno-sedimentation agent and red blood cells under conditions sufficient to form red blood cell rouleaux and allow antibody-antigen binding.Type: ApplicationFiled: March 13, 2013Publication date: October 10, 2013Applicant: CytoSed, Inc.Inventor: Warren L. Dinges -
Publication number: 20130252245Abstract: The invention relates to a method for detecting the presence of a gynaecological growth, in particular for the diagnosis of endometriosis. The invention also relates to a method of identifying a biomarker for detecting the presence of a gynaecological growth and to biomarkers identified by said method.Type: ApplicationFiled: July 19, 2011Publication date: September 26, 2013Inventors: Jacob Vincent Micallef, Mark Edward Eccleston
-
Publication number: 20130252842Abstract: Cyanine dye compounds having a substituted methine moiety that are nucleic acid stains, particularly for fluorescent staining of RNA, including compounds having the formula where R1 is a C1-C6 alkyl, sulfoalkyl, carboxyalkyl or C1-C6 alkoxy; each R2 is independently selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, fused benzo, trifluoromethyl, amino, sulfo, carboxy and halogen, that is optionally further substituted; at least one of R3, R4, and R5 is an alkyl, aryl, heteroaryl, cyclic, or heterocyclic moiety that is optionally substituted by alkyl, amino, aminoalkyl, carboxy, nitro, or halogen; and the remaining R3, R4 or R5 are hydrogen; X is S, O, or Se; and D is a substituted or unsubstituted pyridinium, quinolinium or benzazolium moiety.Type: ApplicationFiled: May 24, 2013Publication date: September 26, 2013Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Jason DALLWIG, David Hagen, Ching-Ying Cheung, Gerald Thomas, Stephen Yue
-
Patent number: 8541242Abstract: The present invention provides assays and devices for detection of substances in liquid samples. The assays and devices utilize passive diffusion between a porous material and a porous membrane containing a specific binding pair member to enable detection of the substance of interest.Type: GrantFiled: June 29, 2011Date of Patent: September 24, 2013Assignee: Techlab, Inc.Inventors: James H. Boone, David M. Lyerly, Tracy D. Wilkins
-
Publication number: 20130230863Abstract: The invention provides systems and methods for transcriptional control which employ target molecules.Type: ApplicationFiled: March 1, 2013Publication date: September 5, 2013Inventors: Chung Yiu Jonathan Tang, Constance L. Cepko
-
Publication number: 20130224758Abstract: The application provides methods for the detection of an analyte in a sample by electrochemiluminescence using certain reagent compositions. Reagent compositions, reagent kits for measuring electrochemiluminescence (ECL) and electrochemiluminescence detection methods using the reagent compositions are disclosed. In particular, the application relates to the use of novel combinations of compounds, which can be used in said measurements to provide improved ECL assay performance.Type: ApplicationFiled: March 15, 2013Publication date: August 29, 2013Applicant: Roche Diagnostics Operations, Inc.Inventors: Andreas Finke, Bernhard Hauptmann, Johannes Stoeckel, Michaela Windfuhr
-
Patent number: 8512980Abstract: Polynucleotides and polypeptides relating to a recombinantly modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, combined such that no foreign sequences are present, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.Type: GrantFiled: May 3, 2012Date of Patent: August 20, 2013Assignee: Grifols Therapeutics Inc.Inventor: Valery Novokhatny